A Long-Term Follow-Up Study of Participants Treated with A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

Launched by A2 BIOTHERAPEUTICS INC. · Mar 18, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to follow up with patients who have previously received gene therapy products from A2 Biotherapeutics for various types of solid tumors, including cancers like colorectal, lung, pancreatic, ovarian, and breast cancers. The main goal of this study is to monitor the long-term safety of these treatments, specifically looking out for any delayed side effects that might occur after the therapy.

To be eligible for this follow-up study, participants must have taken any form of A2 Bio gene therapy in a previous trial and be able to provide written consent to join this long-term study. There are no specific criteria that would exclude anyone from participating. Once enrolled, participants can expect regular check-ins to ensure their health is monitored over time. This study is important for helping researchers understand the long-term effects of gene therapy, which could benefit future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Received any amount of A2 Bio GT product on a previous A2 Bio interventional study
• • 2. Able to provide written informed consent for this long-term follow-up study
• • 3. Able to comply with study requirements
• Exclusion Criteria:
• • 1. There are no specific exclusion criteria for this study